|
|
|
|
|
|
|
|
|
|
Previous: FLEMINGTON PHARMACEUTICAL CORP, 10-K, 2000-11-13 |
Next: FLEMINGTON PHARMACEUTICAL CORP, 10-K, EX-27, 2000-11-13 |
EXHIBIT 11
FLEMINGTON PHARMACEUTICAL CORPORATION
EARNINGS PER SHARE COMPUTATION
YEAR ENDED
JULY 31, 2000
---------------------
BASIC
---------------------
WEIGHTED AVERAGE SHARES OUTSTANDING 4,447,163
DILUTIVE EFFECT OF STOCK PERFORMANCE PLANS (1) --
---------------------
TOTAL 4,447,163
NET INCOME (LOSS) (1,179,000)
---------------------
EARNINGS PER SHARE (.27)
---------------------
YEAR ENDED
JULY 31, 1999
---------------------
BASIC
---------------------
WEIGHTED AVERAGE SHARES OUTSTANDING 3,877,300
DILUTIVE EFFECT OF STOCK PERFORMANCE PLANS (1) --
---------------------
TOTAL 3,877,300
NET INCOME (LOSS) (1,367,000)
---------------------
EARNINGS PER SHARE (.35)
---------------------
(1) SINCE THE COMPANY HAS REPORTED A LOSS FOR EACH PERIOD, NO
POTENTIAL SHARES FROM STOCK PERFORMANCE PLANS HAVE BEEN
PRESENTED, AS THEIR EFFECT WOULD BE ANTI-DILUTIVE.
|
|